• 1990 – 2014  경북대학교 의과대학 생화학교실 교수
• 2015 – 현재   고려대학교 KU-KIST 융합대학원 교수
• 2014 – 현재   KIST 의공학연구소 테라그노시스연구센터 책임연구원

•    Cancer immunotherapy, extracellular vesicle, tumor biology, nanomedicine

논문

• [1] Seong A Kim, Gi-hoon Nam, Young Rang Bae, Saurav Kumar Jah, Seohyun Kim, Yoonjeong Choi, Yeji Lee, Minsu Kwon, Cheolhyun Jeong, Youngro Byun, Jin Woo Park, In-San Kim, Oral Cancer Immunotherapy through a Simvastatin-loaded Colloidal Dispersion System for the Generation of Sustained Antitumor Immunity. Adv Therapeutics, in press, 2021
• [2] H Je, GH Nam, GB Kim, W Kim, SR Kim, IS Kim*, EJ Lee* Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages. J Control Release 331, 7-18, 2021
• [3] Kwon M, Jung H, Nam GH, Kim IS. The right timing, right combination, right sequence, and right delivery for Cancer immunotherapy. J Control Release. Jan 9:S0168-3659(21)00018-3, 2021
• [4] S Kim, SA Kim, GH Nam, Y Hong, GB Kim, Y Choi, S Lee, Y Cho, M Kwon, … In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic … J ImmunoTherapy Cancer 9 (1), e001481, 2021
• [5] Gi-Hoon Nam, Yoonjeong Choi, Gi Beom Kim, Seohyun Kim, Seong A Kim, and In-San Kim Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy. Advanced Materials 2002440, 2020
• [6] GB Kim, GH Nam, Y Hong, J Woo, Y Cho, IC Kwon, Y Yang, IS Kim Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity. Science Advances 6 (27), eaaz2083, 2020
• [7] Y Hong, YK Kim, GB Kim, GH Nam, SA Kim, Y Park, Y Yang, IS Kim Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103+ dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity Journal of Extracellular Vesicles 8 (1), 1670893 2019
• [8] Y Yang, GH Nam, GB Kim, YK Kim, IS Kim, Intrinsic cancer vaccination Advanced Drug Delivery Reviews, 2019
• [9] Y Yang, Y Hong, E Cho, GB Kim, IS Kim, Extracellular vesicles as a platform for membrane-associated therapeutic protein delivery. Journal of extracellular vesicles 7 (1), 1440131, 2018
• [10] M Kih, EJ Lee, NK Lee, YK Kim, KE Lee, C Jeong, Y Yang, DH Kim…, Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages Biomaterials 180, 67-77, 2018
• [11] Gi-Hoon Nam, Eun-Jung Lee, Yoon Kyoung Kim, Yeonsun Hong, Yoonjeong Choi, Myung-Jeom Ryu, Jiwan Woo, Yakdol Cho, Dong June Ahn, Yoosoo Yang, Ick-Chan Kwon, Seung-Yoon Park, and In-San Kim, Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer. Nat. Comm. 2018 Jun 4;9(1):2165.
• [12] Eun Jung Lee, Gi-hoon Nam, Na Kyeong Lee, Minwoo Kih, Eunee Koh,Yoon Kyoung Kim, Yeonsun Hong, Soyoun Kim, Seung-Yoon Park, Cherlhyun Jeong, Yoosoo Yang, and In-San Kim, Nanocage-therapeutics prevailing phagocytosis and immunogenic cell death awakens immunity against cancer. Advanced Materials, 2018 Mar;30(10).
• [13] Y Hong, GH Nam, E Koh, S Jeon, GB Kim, C Jeong, DH Kim, Y Yang, IS Kim, Exosome as a vehicle for delivery of membrane protein therapeutics, PH20, for enhanced tumor penetration and antitumor efficacy. Advanced Functional Materials 28 (5), 1703074, 2018
• [14] Yoosoo Yang, Yeonsun Hong, Gi-Hoon Nam, Jin Hwa Chung, Eunee Koh, and In-San Kim, Virus-mimetic fusogenic exosomes for direct delivery of integral membrane proteins to target cell membranes. Advanced Materials, 2017 Apr;29(13).
• [15] Seung-Yoon Park, Youngeun Yun, Jung-Suk Lim, Mi-Jin Kim, Sang-Yeop Kim, Jung-Eun Kim, & In-San Kim, The phosphatidylserine (PS) receptor stabilin-2 modulates the efficiency of myoblast fusion during myogenic differentiation and muscle regeneration. Nat Comm. 2016 Mar 14;7:10871.
• [16] Taslim A. Al-Hilal, SeungWooChung, Jeong-ukChoi, FarzanaAlam, JoohoPark, SeongWhoKim, FakhrulAhsan, Sang Yoon Kim, In-San Kim*, Youngro Byun*. Prion-like protein “Doppel” is a selective therapeutic target for tumoral angiogenesis. J. Clin. Invest. 2016 Apr 1;126(4):1251-66. *co-corresponding.

특허

• [1] Lipophilic statin composition with improved solubility and permeability and uses thereof
• [2] Deoxycholic acid composition with improved lipolytic effect and preparation method thereof
• [3] Exosomes expressing respiratory syncytial virus F protein and uses thereof
• [4] A novel recombinant epidermal growth factor-exosome and use thereof
• [5] A labeling method of Exosome
• [6] Immune regulatory protein-siRNA complex for anticancer activity
• [7] Anti-tumor Protien conjugated with lysosomal protease activatable probe for specific tumor cell imgaing and composition for imgae comprising the same
• [8] Direct cell conversion technique based on exosome
• [9] A novel anti-cancer fusion protein and use thereof
• [10]A novel pharmaceutical composition for treating cancer